AAIC 2025 Abstract
Anticoagulation as a Limitation to New Alzheimer's Disease Anti‐Amyloid Monoclonal Antibodies therapy
Study in peoplePopulations
Abstract
Background: Over 6 million Americans are living with Alzheimer's disease (AD). AD poses a significant public health challenge.


